Clinical trial • Phase IV • Oncology
Clinical trial in Colorectal cancer (BRAF V600E mutated)
Phase IV trial for Colorectal cancer (BRAF V600E mutated). 53 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Colorectal cancer (BRAF V600E mutated)
- Trial Stage
- Phase IV
Key dates
- Initial CTIS Submission Date
- 27-09-2024
- First CTIS Authorization Date
- 23-10-2024
Trial design
Phase IV trial across 4 sites in Denmark.
- Target Sample Size
- 53
Eligibility
Recruits 53 Vulnerable population not selected..
- Vulnerable Population
- Vulnerable population not selected.
Recruitment
- Planned Sample Size
- 53
- Recruitment Window Months
- 71
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 53
Denmark
- Earliest CTIS Part Ii Submission Date
- 15-10-2024
- Latest Decision Or Authorization Date
- 23-10-2024
- Processing Time Days
- 8
- Number Of Sites
- 4
- Number Of Participants
- 53
Sites
- Site Name
- Odense University Hospital
- Department Name
- Department of Oncology
- Principal Investigator Name
- Per Pfeiffer
- Principal Investigator Email
- per.pfeiffer@rsyd.dk
- Contact Person Name
- Per Pfeiffer
- Contact Person Email
- per.pfeiffer@rsyd.dk
- Site Name
- Nordsjaellands Hospital
- Department Name
- Department of Oncology
- Principal Investigator Name
- Fahimeh Andersen
- Principal Investigator Email
- fahimeh.andersen@regionh.dk
- Contact Person Name
- Fahimeh Andersen
- Contact Person Email
- fahimeh.andersen@regionh.dk
- Site Name
- Aalborg University Hospital
- Department Name
- Department of Oncology
- Principal Investigator Name
- Laurids Poulsen
- Principal Investigator Email
- laop@rn.dk
- Contact Person Name
- Laurids Poulsen
- Contact Person Email
- laop@rn.dk
- Site Name
- Rigshospitalet
- Department Name
- Department of Oncology
- Principal Investigator Name
- Camilla Qvortrup
- Principal Investigator Email
- camilla.qvortrup@regionh.dk
- Contact Person Name
- Camilla Qvortrup
- Contact Person Email
- camilla.qvortrup@regionh.dk
Sponsor
Primary sponsor
- Full Name
- Rigshospitalet
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)